Hanyang Sun

Mr. Hanyang Sun


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2026 in Processes
Verified
Journal Article
Open access
PDF file
MMMaosome of Moeni
Maosome of Moeni
MEMohamed Edokali
Mohamed Edokali
ABAlistair Bacchetti
Alistair Bacchetti
JDJoshua Davy
Joshua Davy
HSHanyang Sun
Hanyang Sun
Ali HassanpourAli Hassanpour
Ali Hassanpour
Oxaliplatin (OXA) is a chemotherapeutic agent that suffers from poor pharmacokinetics and off-target toxicity. To enable controlled OXA release, we engineered a multi-functional iron oxide nanoparticle (IONPs) drug delivery system, based on pH-responsive mesoporous Fe3O4 (Fe3O4@MSN-NH2) nanoparticles (NPs), conjugated with folic acid (FA) for receptor-mediated targeting and guided by a magnetic robot platform (MRP) under simulated physiologically relevant dynamic circulation/flow system. For FA-conjugated NPs (Fe3O4@MSN-NH2/FA), ~29.73% OXA loading was achieved compared to ~10.3% in controls (Fe3O4@MSN-NH2/OXA), quantified by ICP-OES. Under dynamic circulation flow over 48 h, MRP enhanced pH-responsive OXA release (quantified by HPLC-UV), reaching ~92% and 88% (Fe3O4@MSN-NH2/OXA and Fe3O4@MSN-NH2/FA, respectively) at pH 5, versus 47% and 40% (Fe3O4@MSN-NH2/OXA and Fe3O4@MSN-NH2/FA, respectively) without MRP, demonstrating precise control in acidic tumor-mimicking conditions. MRI relaxometry exhibited strong T2-weighted contrast (T2 = 0.015 s at 50 μg/mL for Fe3O4@MSN-NH2/FA/OXA), confirming theranostic potential. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) studies revealed variable Folate receptor alpha (FOLR1) expression among colorectal cancer cell lines (Caco2, SW620, SW48, and T84), with Caco2 demonstrating high levels. MTT assays indicated selective targeting of FOLR1-positive cells by FA-functionalized NPs (Fe3O4@MSN-NH2/FA). This multi-functional drug delivery system integrates targeted delivery, MRP release, and real-time imaging, offering a promising technique for precision oncology.